Roivant Sciences Ltd. (ROIV)
NASDAQ:ROIV
Want to see ROIV full AI Analyst Report?
ROIV Stock Chart & Stats
$29.83
-$0.41(-3.60%)
At close: 4:00 PM EST
$29.83
-$0.41(-3.60%)
Day’s Range― - ―
52-Week Range$10.71 - $32.79
Previous CloseN/A
Volume1.46M
Average Volume (3M)6.27M
Market Cap
$21.57B
Enterprise Value$20.26B
Total Cash (Recent Filing)$4.30B
Total Debt (Recent Filing)$107.44M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Aug 17, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding719,270,400
10 Day Avg. Volume8,225,967
30 Day Avg. Volume6,267,258
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)4.25
Price to Sales (P/S)2326.88
P/FCF Ratio-25.34
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue2.45K
Enterprise Value/Gross Profit2.90K
Enterprise Value/Ebitda-15.80
Forecast
1Y Price Target
$37.83Price Target Upside26.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.26
Revenue Forecast (FY)$76.52M
Bulls Say, Bears Say
Bulls Say
Capital Allocation And Share RepurchasesSettlement proceeds provide tangible cash that can be deployed to fund the drug pipeline, pursue business development, and support increased share repurchases to improve shareholder returns.
Intellectual Property ValidationSettlement with Moderna produced consented judgments of infringement and no invalidity, validating the firm's lipid nanoparticle patents and crystallizing non-operating value that can support a higher valuation.
Regulatory And Clinical Upside For Lead TherapyRegulatory acceptance of the brepocitinib filing for dermatomyositis with priority review, together with strong Phase 2 results in cutaneous sarcoidosis, strengthens the drug's multi-indication commercial potential and represents upside not fully captured in current models.
Bears Say
Appellate And Contingent Payment UncertaintyContingent settlement payments remain tied to an appeals outcome, creating material uncertainty that could delay or reduce expected cash inflows and limit near-term valuation improvement.
Clinical And Regulatory Execution RiskSeveral important late-stage trials and regulatory milestones are still pending, and disappointing readouts or regulatory setbacks could trigger meaningful share downside given parts of the pipeline appear priced into the stock.
Liquidity Pressure And Competitive RiskHigh cash burn combined with the prospect of weaker commercial uptake amid growing therapeutic competition could pressure liquidity and force changes to development plans or capital structure.
Roivant Sciences News
ROIV FAQ
What was Roivant Sciences Ltd.’s price range in the past 12 months?
Roivant Sciences Ltd. lowest stock price was $10.71 and its highest was $32.79 in the past 12 months.
What is Roivant Sciences Ltd.’s market cap?
Roivant Sciences Ltd.’s market cap is $21.57B.
When is Roivant Sciences Ltd.’s upcoming earnings report date?
Roivant Sciences Ltd.’s upcoming earnings report date is Aug 17, 2026 which is in 77 days.
How were Roivant Sciences Ltd.’s earnings last quarter?
Roivant Sciences Ltd. released its earnings results on May 20, 2026. The company reported $0.279 earnings per share for the quarter, beating the consensus estimate of -$0.289 by $0.568.
Is Roivant Sciences Ltd. overvalued?
According to Wall Street analysts Roivant Sciences Ltd.’s price is currently Undervalued.
Does Roivant Sciences Ltd. pay dividends?
Roivant Sciences Ltd. does not currently pay dividends.
What is Roivant Sciences Ltd.’s EPS estimate?
Roivant Sciences Ltd.’s EPS estimate is -0.3.
How many shares outstanding does Roivant Sciences Ltd. have?
Roivant Sciences Ltd. has 719,270,400 shares outstanding.
What happened to Roivant Sciences Ltd.’s price movement after its last earnings report?
Roivant Sciences Ltd. reported an EPS of $0.279 in its last earnings report, beating expectations of -$0.289. Following the earnings report the stock price went up 14.888%.
Which hedge fund is a major shareholder of Roivant Sciences Ltd.?
Currently, no hedge funds are holding shares in ROIV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Roivant Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.83 (26.83% Upside)
$37.83 (26.83% Upside)
Blogger Sentiment
Bullish
ROIV Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 10.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $29.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 15.2%
Last 30 Days ▲ 15.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
165.39%
12-Months-Change
Fundamentals
Return on Equity
-6.85%
Trailing 12-Months
Asset Growth
5.35%
Trailing 12-Months
Company Description
Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
ROIV Company Deck
ROIV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple strong clinical signals (notably the robust open-label 1402 RA responses and mosli hemodynamic activity), solid financial backing (cash of $4.3B and a $2.25B Moderna settlement), and rapid execution across trials and commercial prep. Key risks were acknowledged: interpretability limitations from open-label data, potential difficulty meeting the randomized withdrawal primary endpoint for 1402, some program failures (bitokamab), pending biomarker analyses, and competitive/ regulatory hurdles in indications like CLE and PH-ILD. On balance, the pipeline momentum, cash position, and high-impact data presented outweigh the noted challenges, though important uncertainties remain that will require follow-up data and regulatory feedback.View all ROIV earnings summariesROIV Stock 12 Month Forecast
Average Price Target
$37.83
▲(26.83% Upside)
Technical Analysis
Ownership Overview
19.98% Insiders
16.58% Mutual Funds
21.20% Other Institutional Investors
28.29% Public Companies and
Individual Investors